Among these therapies, anti-TNF-α biologics represent the front line of treatment for active RA.4 However, the efficacy of these treatments is still limited, and there is uncertainty about long-term safety.5, 6, 38 We revealed here that hUCB-MSCs can remarkably suppress NLRP3 inflammasome-mediated IL-1β production, as well as TNF-α secretion. This evidence concerns the gene IL1B and rheumatoid arthritis.